Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Elan Corporation, plc (ELN) -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (1927)	3/22/2002 10:49:28 AM
From: Harold Engstrom	Respond to of 10345

Thanks for pointing this out. Elan's Ligand invest appears to be worth about $250MM now. H

To: Icebrg who wrote (1927)	3/23/2002 7:30:55 PM
From: scaram(o)uche	Read Replies (2) \| Respond to of 10345

>> Elan has today put an amended 20-F on their website. (For the year 2000) << Thanks, Ice. Under "KEY RESEARCH AND DEVELOPMENT PRODUCT PIPELINE", they list an undisclosed product in phase III testing, partnered with Merck. I am still relatively new to ELN, filling in pieces. Does anyone here know what product this is?? TIA.

To: Icebrg who wrote (1927)	3/24/2002 9:02:11 AM
From: twentyfirstcenturyfox	Read Replies (1) \| Respond to of 10345

Thanks for that, Iceberg. I see that one of the Euro brokerage houses that has been a major follower of Elan, GOODBODY's, has issued an updated commentary. I am typing below the latest (March 2002) comment on Elan as follows: "On the back of accounting issues and the suspension of dosing in its AN-1792 trial for Alzheimer's disease, the company issued a profit warning with its FY 2001 year end results guiding earnings some 34% lower for 2002 than consensus. Given a slow down in existing revenue driver growth, an increasing cost base and questions on the applicability and sustainability of certain "revenue" items, we have re-evaluated our product model and consider the company's guidance optimistic. We forecast fully diluted earnings for 2002 of $1.12 per share (52% below previous consensus), rising to $1.20 and $1.34 in 2003 and 2004 respectively." For the first time, they make no recommendation regarding Elan. Fox.